Document is current
Any future updates will be listed below
-
Authors
Norris, Madeline L.
DeRemer, David L.
Duarte, Julio D.
Kim, George P.
George, Thomas J.
-
Funding
Funding for this research was provided by:
NIH/NHGRI (R01HG013416 and R01HG011800)
- License Information
-
More Information
Article History
Received: 11 August 2025
Accepted: 18 October 2025
First Online: 21 November 2025
Declarations
:
: DD - Non-financial compensation consultation with Astra Zeneca.; TJG - DSMB: Seagen, Nihon Medi-Physics, KAHR Medical, Arbele; Consultant: Avammune Therapeutics, BillionToOne, Exact Sciences, Summit Therapeutics; Research Support (to institution): Bristol-Myers Squibb, Merck, AstraZeneca, Lilly, Bayer, Incyte, Ipsen, Genentech, Astellas Pharma, GlaxoSmithKline, Amgen, OncoC4, BillionToOne, Jounce Therapeutics, Elicio Therapeutics, AMAL Therapeutics/Boehringer Ingelheim, Seagen, Regeneron, Deciphera.
